U.S. Markets closed
  • S&P Futures

    3,782.75
    -34.00 (-0.89%)
     
  • Dow Futures

    31,020.00
    -216.00 (-0.69%)
     
  • Nasdaq Futures

    12,532.75
    -149.00 (-1.17%)
     
  • Russell 2000 Futures

    2,180.00
    -25.80 (-1.17%)
     
  • Crude Oil

    61.60
    +0.32 (+0.52%)
     
  • Gold

    1,708.50
    -7.30 (-0.43%)
     
  • Silver

    26.10
    -0.29 (-1.09%)
     
  • EUR/USD

    1.2051
    -0.0016 (-0.1326%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3936
    -0.0017 (-0.1185%)
     
  • USD/JPY

    107.0370
    +0.0350 (+0.0327%)
     
  • BTC-USD

    49,747.37
    +931.98 (+1.91%)
     
  • CMC Crypto 200

    995.03
    +6.93 (+0.70%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    28,720.95
    -838.15 (-2.84%)
     

Reflecting on AcelRx Pharmaceuticals' (NASDAQ:ACRX) Share Price Returns Over The Last Three Years

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

This month, we saw the AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) up an impressive 39%. Meanwhile over the last three years the stock has dropped hard. Tragically, the share price declined 60% in that time. Some might say the recent bounce is to be expected after such a bad drop. While many would remain nervous, there could be further gains if the business can put its best foot forward.

View our latest analysis for AcelRx Pharmaceuticals

Because AcelRx Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last three years AcelRx Pharmaceuticals saw its revenue shrink by 68% per year. That means its revenue trend is very weak compared to other loss making companies. With no profits and falling revenue it is no surprise that investors have been dumping the stock, pushing the price down by 17% per year over that time. When revenue is dropping, and losses are still costing, and the share price sinking fast, it's fair to ask if something is remiss. It could be a while before the company repays long suffering shareholders with share price gains.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think AcelRx Pharmaceuticals will earn in the future (free profit forecasts).

A Different Perspective

AcelRx Pharmaceuticals shareholders are down 23% for the year, but the market itself is up 15%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 7.3% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that AcelRx Pharmaceuticals is showing 3 warning signs in our investment analysis , you should know about...

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.